Tag: 上海后花园OWC

first_img Log In | Learn More STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. Biotech Vertex to pay startup Kymera $70 million in R&D deal Vertex Pharmaceuticals, the Boston biotech best known for its portfolio of drugs to treat cystic fibrosis, will pay $70 million up front to a Cambridge, Mass., startup that hopes to use a novel approach to treat diseases. It will initially focus on inflammatory disorders and cancers, but the science could potentially apply to a broad range of illnesses.Vertex announced a four-year research and development collaboration Wednesday with Kymera Therapeutics. The privately held startup wants to develop drugs based on Nobel Prize-winning insights into how the body eliminates disease-causing proteins. Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+. First 30 days free. GET STARTED What is it? Jonathan Saltzman — Boston Globe GET STARTED About the Author Reprints What’s included? By Jonathan Saltzman — Boston Globe May 15, 2019 Reprints Scientists at work at Vertex Pharmaceuticals. Barry Chin/The Boston Globe Tags biotechnologyBostondrug developmentfinancerare diseaseSTAT+last_img read more

Read more